{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:34:32Z","timestamp":1787315672361,"version":"build-2736575974"},"reference-count":121,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"NIH","award":["1R01DK124412"],"award-info":[{"award-number":["1R01DK124412"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Hepatic porphyrias are a group of metabolic disorders that are characterized by overproduction and accumulation of porphyrin precursors in the liver. These porphyrins cause neurologic symptoms as well as cutaneous photosensitivity, and in some cases patients can experience life-threatening acute neurovisceral attacks. This review describes the acute hepatic porphyrias in detail, including acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria, as well as the hepatic porphyrias with cutaneous manifestations such as porphyria cutanea tarda and hepatoerythropoietic porphyria. Each section will cover disease prevalence, clinical manifestations, and current therapies, including strategies to manage symptoms. Finally, we review new and emerging treatment modalities, including gene therapy through use of adeno-associated vectors and chaperone therapies such as lipid nanoparticle and small interfering RNA-based therapeutics.<\/jats:p>","DOI":"10.1055\/s-0044-1787076","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:20:41Z","timestamp":1715973641000},"page":"209-225","source":"Crossref","is-referenced-by-count":5,"title":["Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs"],"prefix":"10.1055","volume":"44","author":[{"given":"Oluwashanu","family":"Balogun","sequence":"additional","affiliation":[{"name":"Department of Experimental Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Nejak-Bowen","sequence":"additional","affiliation":[{"name":"Department of Experimental Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Pittsburgh Liver Institute, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"issue":"9718","key":"ref1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"H Puy","year":"2010","journal-title":"Lancet"},{"key":"ref2","volume-title":"Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias","author":"K E Anderson","year":"2001"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clinre.2015.05.009","article-title":"Porphyrias: A 2015 update","volume":"39","author":"Z Karim","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"23","key":"ref4","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood-2012-05-423186","article-title":"The porphyrias: advances in diagnosis and treatment","volume":"120","author":"M Balwani","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1055\/s-0043-1776760","article-title":"The hepatic porphyrias: revealing the complexities of a rare disease","volume":"43","author":"O Balogun","year":"2023","journal-title":"Semin Liver Dis"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood-2008-02-138222","article-title":"Down-regulation of hepcidin in porphyria cutanea tarda","volume":"112","author":"R S Ajioka","year":"2008","journal-title":"Blood"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","article-title":"Heme biosynthesis and the porphyrias","volume":"128","author":"J D Phillips","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbamcr.2006.05.005","article-title":"Biosynthesis of heme in mammals","volume":"1763","author":"R S Ajioka","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"ref9","author":"A S Ogun","year":"2024"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"a011676","DOI":"10.1101\/cshperspect.a011676","article-title":"Erythroid heme biosynthesis and its disorders","volume":"3","author":"H A Dailey","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref11","volume-title":"Porphyrias: an overview","author":"K E Anderson"},{"issue":"35","key":"ref12","doi-asserted-by":"crossref","first-page":"26753","DOI":"10.1074\/jbc.R110.119503","article-title":"Iron and porphyrin trafficking in heme biogenesis","volume":"285","author":"I J Schultz","year":"2010","journal-title":"J Biol Chem"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2019.01.015","article-title":"Regulation and tissue-specific expression of \u03b4-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias","volume":"128","author":"K Peoc\u2019h","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/paa.1999.111.5.438","article-title":"Heme oxygenase: recent advances in understanding its regulation and role","volume":"111","author":"K K Elbirt","year":"1999","journal-title":"Proc Assoc Am Physicians"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-78518-9","volume-title":"Tetrapyrroles Birth, Life and Death","author":"M JSAG Warren","year":"2009"},{"issue":"22","key":"ref17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/BF01486762","article-title":"Hepatic porphyrins and urinary porphyrins and porphyrin precursors in liver cirrhosis","volume":"50","author":"M Doss","year":"1972","journal-title":"Klin Wochenschr"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1182\/blood.V97.10.2972","article-title":"Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria","volume":"97","author":"M Maruno","year":"2001","journal-title":"Blood"},{"key":"ref20","volume-title":"Ala Dehydratase Deficiency Porphyria","author":"G Mohan","year":"2023"},{"key":"ref21","first-page":"2103","volume-title":"The porphyrias","author":"A Kappas","year":"1995"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2005.10.011","article-title":"delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations","volume":"87","author":"R Akagi","year":"2006","journal-title":"Mol Genet Metab"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2007-1007139","article-title":"Acute porphyrias: pathogenesis of neurological manifestations","volume":"18","author":"U A Meyer","year":"1998","journal-title":"Semin Liver Dis"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5041\/RMMJ.10333","article-title":"Porphyria: what is it and who should be evaluated?","volume":"9","author":"Y Edel","year":"2018","journal-title":"Rambam Maimonides Med J"},{"key":"ref25","first-page":"373","volume-title":"10 - Inherited Porphyrias","author":"R J Desnick","year":"2021"},{"key":"ref26","first-page":"448","volume-title":"Photosensitivity and photoreactions","author":"A Paller","year":"2016"},{"issue":"6494","key":"ref27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/bmj.291.6494.505","article-title":"Genetic heterogeneity in acute intermittent porphyria: characterisation and frequency of porphobilinogen deaminase mutations in Finland","volume":"291","author":"P Mustajoki","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"5722","key":"ref28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/280514a0","article-title":"\u03b4-aminolaevulinic acid is a potent agonist for GABA autoreceptors","volume":"280","author":"M JW Brennan","year":"1979","journal-title":"Nature"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0954-6820.1976.tb08216.x","article-title":"Hereditary hepatic porphyrias in Finland","volume":"200","author":"P Mustajoki","year":"1976","journal-title":"Acta Med Scand"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddy030","article-title":"From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria","volume":"27","author":"H Lenglet","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1034\/j.1399-0004.2002.620406.x","article-title":"Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene","volume":"62","author":"Y Floderus","year":"2002","journal-title":"Clin Genet"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/humu.23067","article-title":"Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease","volume":"37","author":"B Chen","year":"2016","journal-title":"Hum Mutat"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s004390000356","article-title":"Non-erythroid form of acute intermittent porphyria caused by promoter and frameshift mutations distant from the coding sequence of exon 1 of the HMBS gene","volume":"107","author":"S D Whatley","year":"2000","journal-title":"Hum Genet"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14218\/JCTH.2014.00039","article-title":"Acute hepatic porphyria","volume":"3","author":"D M Bissell","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"ref35","volume-title":"Acute intermittent porphyria","author":"S D Whatley","year":"1993"},{"issue":"19","key":"ref36","first-page":"3211","article-title":"Brain ventricular enlargement in human and murine acute intermittent porphyria","volume":"29","author":"D Jeric\u00f3","year":"2020","journal-title":"Hum Mol Genet"},{"key":"ref37","volume-title":"Acute Intermittent Porphyria","author":"L F Gonzalez-Mosquera","year":"2023"},{"issue":"05","key":"ref38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/practneurol-2017-001878","article-title":"Porphyria: often discussed but too often missed","volume":"18","author":"R O'Malley","year":"2018","journal-title":"Pract Neurol"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2796.2010.02335.x","article-title":"Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden","volume":"269","author":"E Innala","year":"2011","journal-title":"J Intern Med"},{"key":"ref40","volume-title":"Hereditary coproporphyria","author":"B Wang","year":"1993"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1681\/ASN.2016080918","article-title":"A variant of peptide transporter 2 predicts the severity of porphyria-associated kidney disease","volume":"28","author":"D Tchernitchko","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref42","first-page":"26","volume-title":"Porphyria","author":"R Gugig","year":"2003"},{"issue":"09","key":"ref43","doi-asserted-by":"crossref","first-page":"801.e19","DOI":"10.1016\/j.amjmed.2006.05.026","article-title":"Open-label study of hemin for acute porphyria: clinical practice implications","volume":"119","author":"K E Anderson","year":"2006","journal-title":"Am J Med"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2019.05.003","article-title":"Current and innovative emerging therapies for porphyrias with hepatic involvement","volume":"71","author":"A Fontanellas","year":"2019","journal-title":"J Hepatol"},{"issue":"09","key":"ref45","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"D M Bissell","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17512433.2022.2075848","article-title":"Givosiran for the treatment of acute hepatic porphyria","volume":"15","author":"A Ricci","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9410","key":"ref47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(04)15646-8","article-title":"Liver transplantation as a cure for acute intermittent porphyria","volume":"363","author":"Z F Soonawalla","year":"2004","journal-title":"Lancet"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1432-2277.2009.01035.x","article-title":"Combined liver and kidney transplantation in acute intermittent porphyria","volume":"23","author":"S Wahlin","year":"2010","journal-title":"Transpl Int"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/hmg\/ddz003","article-title":"Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria","volume":"28","author":"M Yasuda","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1440-0960.2011.00747.x","article-title":"Haem arginate as effective maintenance therapy for hereditary coproporphyria","volume":"52","author":"E Ma","year":"2011","journal-title":"Australas J Dermatol"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","article-title":"The incidence of inherited porphyrias in Europe","volume":"36","author":"G Elder","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/clinchem\/38.1.96","article-title":"Fecal coproporphyrin isomers in hereditary coproporphyria","volume":"38","author":"D Blake","year":"1992","journal-title":"Clin Chem"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jmd2.12281","article-title":"High penetrance, recurrent attacks and thrombus formation in a family with hereditary coproporphyria","volume":"63","author":"C Towns","year":"2022","journal-title":"JIMD Rep"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0009-9120(00)00159-4","article-title":"Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients","volume":"33","author":"A K\u00fchnel","year":"2000","journal-title":"Clin Biochem"},{"issue":"24","key":"ref55","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"M Balwani","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"ref56","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJM199105163242005","article-title":"Bile porphyrin analysis in the evaluation of variegate porphyria","volume":"324","author":"G M Logan","year":"1991","journal-title":"N Engl J Med"},{"issue":"07","key":"ref57","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/eci.12091","article-title":"Antioxidants restore protoporphyrinogen oxidase in variegate porphyria patients","volume":"43","author":"M D Ferrer","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0020-711X(80)90173-1","article-title":"The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town","volume":"12","author":"L Eales","year":"1980","journal-title":"Int J Biochem"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.ejhg.5200860","article-title":"Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients","volume":"10","author":"M von und zu Fraunberg","year":"2002","journal-title":"Eur J Hum Genet"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.1993.tb03303.x","article-title":"Detection of latent variegate porphyria by fluorescence emission spectroscopy of plasma","volume":"129","author":"C Long","year":"1993","journal-title":"Br J Dermatol"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/ced.12071","article-title":"Homozygous variegate porphyria presenting with developmental and language delay in childhood","volume":"38","author":"V A Pinder","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng0596-95","article-title":"A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria","volume":"13","author":"P N Meissner","year":"1996","journal-title":"Nat Genet"},{"key":"ref63","volume-title":"Variegate porphyria","author":"A K Singal","year":"2013"},{"key":"ref64","first-page":"515","volume-title":"Andrews' Diseases of the Skin. 13th ed","author":"D J William","year":"2020"},{"key":"ref65","first-page":"593","volume-title":"Metabolic and storage diseases","author":"J W Patterson","year":"2010"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2017_2","article-title":"An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom","volume":"36","author":"D Schulenburg-Brand","year":"2017","journal-title":"JIMD Rep"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/8904_2015_411","article-title":"Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms","volume":"22","author":"J T Marsden","year":"2015","journal-title":"JIMD Rep"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2340\/00015555-0870","article-title":"Hepatocellular carcinoma in variegate porphyria: a serious complication","volume":"90","author":"X Schneider-Yin","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2019.01.004","article-title":"Porphyria cutanea tarda: recent update","volume":"128","author":"A K Singal","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/phpp.12640","article-title":"Porphyria cutanea tarda presenting as a lichenoid eruption","volume":"37","author":"A Toussi","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00295407","article-title":"Familial and sporadic porphyria cutanea: two different diseases","volume":"44","author":"H de Verneuil","year":"1978","journal-title":"Hum Genet"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM197808102990603","article-title":"Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda","volume":"299","author":"G H Elder","year":"1978","journal-title":"N Engl J Med"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0741-8329(03)00127-7","article-title":"Iron as a co-morbid factor in nonhemochromatotic liver disease","volume":"30","author":"H L Bonkovsky","year":"2003","journal-title":"Alcohol"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/hep.510270627","article-title":"Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America","volume":"27","author":"H L Bonkovsky","year":"1998","journal-title":"Hepatology"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MD.0b013e3181d50928","article-title":"Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients","volume":"89","author":"C Mu\u00f1oz-Santos","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1111\/ijd.13580","article-title":"Porphyria cutanea tarda: an intriguing genetic disease and marker","volume":"56","author":"N S Handler","year":"2017","journal-title":"Int J Dermatol"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2362.1981.tb02014.x","article-title":"Abnormal haem biosynthesis in chronic alcoholics","volume":"11","author":"K E McColl","year":"1981","journal-title":"Eur J Clin Invest"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1111\/j.1600-0625.2009.01040.x","article-title":"Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda","volume":"19","author":"A Fontanellas","year":"2010","journal-title":"Exp Dermatol"},{"issue":"08","key":"ref79","first-page":"845","article-title":"Precipitating\/aggravating factors of porphyria cutanea tarda in Spanish patients","volume":"48","author":"J Cruz-Rojo","year":"2002","journal-title":"Cell Mol Biol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12659\/AJCR.889955","article-title":"Hepatitis C- and HIV-induced porphyria cutanea tarda","volume":"15","author":"R Quansah","year":"2014","journal-title":"Am J Case Rep"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2007.10.011","article-title":"Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription","volume":"134","author":"S Nishina","year":"2008","journal-title":"Gastroenterology"},{"issue":"09","key":"ref82","first-page":"2","article-title":"Porphyria cutanea tarda induced by tamoxifen","volume":"16","author":"M J Cruz","year":"2010","journal-title":"Dermatol Online J"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1067\/mlc.2000.111024","article-title":"Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda","volume":"136","author":"Z J Bulaj","year":"2000","journal-title":"J Lab Clin Med"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archderm.1970.04000090022004","article-title":"Estrogen-induced porphyria cutanea tarda. Report of three cases","volume":"102","author":"H H Roenigk Jr","year":"1970","journal-title":"Arch Dermatol"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0190-9622(98)70119-7","article-title":"Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients","volume":"38","author":"G E Gibson","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref86","first-page":"4591871","article-title":"Porphyria cutanea tarda in a patient with end-stage renal disease: a case of successful treatment with deferoxamine and ferric carboxymaltose","volume":"2017","author":"N Rodrigues","year":"2017","journal-title":"Case Rep Nephrol"},{"issue":"07","key":"ref87","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/ijd.13938","article-title":"Diagnosing diabetes mellitus in patients with porphyria cutanea tarda","volume":"57","author":"A L Christiansen","year":"2018","journal-title":"Int J Dermatol"},{"issue":"04","key":"ref88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0781.1997.tb00218.x","article-title":"Porphyria cutanea tarda and hematologic malignancy\u2013a report of 4 cases","volume":"13","author":"D B McKenna","year":"1997","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref89","volume-title":"Familial porphyria cutanea tarda","author":"S Rudnick","year":"1993"},{"issue":"06","key":"ref90","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1478-3231.2012.02794.x","article-title":"Hepatitis C, porphyria cutanea tarda and liver iron: an update","volume":"32","author":"F Ryan Caballes","year":"2012","journal-title":"Liver Int"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/hep.21885","article-title":"Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls","volume":"46","author":"C Ellervik","year":"2007","journal-title":"Hepatology"},{"issue":"08","key":"ref92","first-page":"1557","article-title":"Hepatoerythropoietic porphyria: neuroimaging findings","volume":"18","author":"J Berenguer","year":"1997","journal-title":"AJNR Am J Neuroradiol"},{"issue":"03","key":"ref93","first-page":"613","article-title":"Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria","volume":"36","author":"H de Verneuil","year":"1984","journal-title":"Am J Hum Genet"},{"key":"ref94","volume-title":"Hepatoerythropoietic Porphyria","author":"S Rudnick","year":"1993"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2010.89","article-title":"Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation","volume":"146","author":"J L Cantatore-Francis","year":"2010","journal-title":"Arch Dermatol"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1005313024076","article-title":"Hepatic porphyrias in children","volume":"20","author":"G H Elder","year":"1997","journal-title":"J Inherit Metab Dis"},{"issue":"06","key":"ref97","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","article-title":"Recommendations for the diagnosis and treatment of the acute porphyrias","volume":"142","author":"K E Anderson","year":"2005","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref98","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13023-022-02314-9","article-title":"Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives","volume":"17","author":"M Marcacci","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"ref99","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/clinchem\/41.11.1670a","article-title":"Is the Watson-Schwartz screening method for porphobilinogen reliable?","volume":"41","author":"J E Buttery","year":"1995","journal-title":"Clin Chem"},{"issue":"7250","key":"ref100","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/bmj.320.7250.1647","article-title":"Diagnosis and management of porphyria","volume":"320","author":"H Thadani","year":"2000","journal-title":"BMJ"},{"issue":"12","key":"ref101","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"H L Bonkovsky","year":"2014","journal-title":"Am J Med"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-020-01328-w","article-title":"Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study","volume":"18","author":"J Andersen","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"17","key":"ref103","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/archinte.1993.00410170078008","article-title":"Early administration of heme arginate for acute porphyric attacks","volume":"153","author":"P Mustajoki","year":"1993","journal-title":"Arch Intern Med"},{"issue":"05","key":"ref104","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jhep.2023.06.013","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial","volume":"79","author":"D J Kuter","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"ref105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/13696998.2020.1835306","article-title":"Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP)","volume":"23","author":"S Massachi","year":"2020","journal-title":"J Med Econ"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/8904_2015_458","article-title":"Liver fibrosis associated with iron accumulation due to long-term heme-arginate treatment in acute intermittent porphyria: a case series","volume":"25","author":"B Willandt","year":"2016","journal-title":"JIMD Rep"},{"issue":"01","key":"ref107","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.12750","article-title":"Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver","volume":"284","author":"C Schmitt","year":"2018","journal-title":"J Intern Med"},{"issue":"04","key":"ref108","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jimd.12391","article-title":"Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran","volume":"44","author":"J To-Figueras","year":"2021","journal-title":"J Inherit Metab Dis"},{"issue":"03","key":"ref109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/biomedicines10030648","article-title":"Cutting-edge therapies and novel strategies for acute intermittent porphyria: step-by-step towards the solution","volume":"10","author":"M Longo","year":"2022","journal-title":"Biomedicines"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/mt.2009.250","article-title":"AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function","volume":"18","author":"M Yasuda","year":"2010","journal-title":"Mol Ther"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2010.210","article-title":"Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice","volume":"19","author":"C Unzu","year":"2011","journal-title":"Mol Ther"},{"issue":"03","key":"ref112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jhep.2009.09.003","article-title":"Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria","volume":"52","author":"C Unzu","year":"2010","journal-title":"J Hepatol"},{"issue":"04","key":"ref113","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","article-title":"Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria","volume":"65","author":"D D'Avola","year":"2016","journal-title":"J Hepatol"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"A Meliani","year":"2018","journal-title":"Nat Commun"},{"issue":"21","key":"ref115","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1093\/hmg\/ddy283","article-title":"Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria","volume":"27","author":"I Serrano-Mendioroz","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"04","key":"ref116","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/hum.2017.056","article-title":"An inducible promoter responsive to different porphyrinogenic stimuli improves gene therapy vectors for acute intermittent porphyria","volume":"29","author":"I Serrano-Mendioroz","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"02","key":"ref117","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymthe.2019.11.010","article-title":"A pharmacological chaperone therapy for acute intermittent porphyria","volume":"28","author":"H J Bustad","year":"2020","journal-title":"Mol Ther"},{"issue":"627","key":"ref118","doi-asserted-by":"crossref","first-page":"eabc0700","DOI":"10.1126\/scitranslmed.abc0700","article-title":"Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria","volume":"14","author":"K M C\u00f3rdoba","year":"2022","journal-title":"Sci Transl Med"},{"issue":"12","key":"ref119","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"L Jiang","year":"2018","journal-title":"Nat Med"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-pathol-020117-044010","article-title":"Wnt\/\u03b2-catenin signaling in liver development, homeostasis, and pathobiology","volume":"13","author":"J O Russell","year":"2018","journal-title":"Annu Rev Pathol"},{"issue":"01","key":"ref121","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2018.09.023","article-title":"Loss of hepatocyte \u03b2-catenin protects mice from experimental porphyria-associated liver injury","volume":"70","author":"H Saggi","year":"2019","journal-title":"J Hepatol"},{"issue":"03","key":"ref122","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ymgme.2019.01.007","article-title":"Murine models of the human porphyrias: contributions toward understanding disease pathogenesis and the development of new therapies","volume":"128","author":"M Yasuda","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"06","key":"ref123","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"E Sardh","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T05:51:10Z","timestamp":1730785870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":121,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,7,12]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787076","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}